Pan-Cancer Analysis of PIMREG as a Biomarker for the Prognostic and Immunological Role

Hua Zhu; Xinyao Hu; Yingze Ye; Zhihong Jian; Yi Zhong; Lijuan Gu; Xiaoxing Xiong

doi:10.3389/fgene.2021.687778

Pan-Cancer Analysis of PIMREG as a Biomarker for the Prognostic and Immunological Role

Front Genet. 2021 Sep 14:12:687778. doi: 10.3389/fgene.2021.687778. eCollection 2021.

Authors

Hua Zhu^{1

2}, Xinyao Hu^{2

3}, Yingze Ye¹, Zhihong Jian¹, Yi Zhong^{1

2}, Lijuan Gu^{2

4}, Xiaoxing Xiong^{1

2}

Affiliations

¹ Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
² Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
³ Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
⁴ Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, China.

Abstract

Phosphatidylinositol binding clathrin assembly protein interacting mitotic regulator (PIMREG) localizes to the nucleus and can significantly elevate the nuclear localization of clathrin assembly lymphomedullary leukocythemia gene. Although there is some evidence to support an important action for PIMREG in the occurrence and development of certain cancers, currently no pan-cancer analysis of PIMREG is available. Therefore, we intended to estimate the prognostic predictive value of PIMREG and to explore its potential immune function in 33 cancer types. By using a series of bioinformatics approaches, we extracted and analyzed datasets from Oncomine, The Cancer Genome Atlas, Cancer Cell Lineage Encyclopedia (CCLE) and the Human Protein Atlas (HPA), to explore the underlying carcinogenesis of PIMREG, including relevance of PIMREG to prognosis, microsatellite instability (MSI), tumor mutation burden (TMB), tumor microenvironment (TME) and infiltration of immune cells in various types of cancer. Our findings indicate that PIMREG is highly expressed in at least 24 types of cancer, and is negatively correlated with prognosis in major cancer types. In addition, PIMREG expression was correlated with TMB in 24 cancers and with MSI in 10 cancers. We revealed that PIMREG is co-expressed with genes encoding major histocompatibility complex, immune activation, immune suppression, chemokine and chemokine receptors. We also found that the different roles of PIMREG in the infiltration of different immune cell types in different tumors. PIMREG can potentially influence the etiology or pathogenesis of cancer by acting on immune-related pathways, chemokine signaling pathway, regulation of autophagy, RIG-I like receptor signaling pathway, antigen processing and presentation, FC epsilon RI pathway, complement and coagulation cascades, T cell receptor pathway, NK cell mediated cytotoxicity and other immune-related pathways. Our study suggests that PIMREG can be applied as a prognostic marker in a variety of malignancies because of its role in tumorigenesis and immune infiltration.

Keywords: MSI; PIMREG; TMB; pan-cancer; prognosis; tumor immunity.